Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 12:49 PM ET


Company Overview of Fabrus, LLC

Company Overview

Fabrus, LLC, a biotechnology company, engages in discovering, developing, and engineering therapeutic antibodies. Its antibodies hit in various stages of development against the cancer targets DLL4, ErbB1 (EGFR), ErbB2 (Her2), ErbB3, P-Cadherin, c-Ron, c-Met, Axl, and several undisclosed targets. The company also offers cell-based discoveries that allow direct screening for antibody leads on intact cells; technologies to achieve affinity maturation, internalization, and pH dependent binding optimization for recombinant antibodies; and technologies to use flow cytometry to achieve multiplexed discovery directly on living cells. Fabrus, LLC was founded in 2007 and is based in La Jolla, Califor...

11099 North Torrey Pines Road

Suite 230

La Jolla, CA 92037

United States

Founded in 2007



Key Executives for Fabrus, LLC

Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Fabrus, LLC Key Developments

Fabrus, LLC Auditor Raises 'Going Concern' Doubt

Fabrus, LLC filed its Annual on Jul 25, 2014 for the period ending Dec 31, 2013. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Senesco Technologies Inc. and Fabrus Announces New Members to its Board of Combined Company

The Board of Directors of the combined company of Senesco Technologies Inc. and Fabrus Inc. is chaired by Dr. Harlan Waksal, founder of ImClone Systems and also includes: Dr. Philip Frost, Chairman and CEO of Opko Health Inc. and the Chairman of Teva Pharmaceuticals; Mr. Christopher Forbes, Vice Chair, Forbes Media, LLC; Mr. David Rector, Principal, David Stephen Group; Mr. John N. Braca; Former, Venture and Operational Investor, SR One and EuclidSR Partners; Dr. Vaughn V. Smider, Chief Scientific Officer and acting CEO, Senesco; Mr. Steven D. Rubin, Executive Vice President at OPKO Health Inc. The officers of the combined company are: Dr. Vaughn V. Smider, Chief Scientific Officer and acting CEO; Dr. Leslie J. Browne, President; Joel Brooks, Chief Financial Officer, Treasurer and Secretary; Dr. James Graziano, Chief Technology Officer; Dr. Miguel de los Rios, Vice President, Research; Professor John E. Thompson, Scientific Founder; Richard Dondero, Vice President, Preclinical Development.

Similar Private Companies By Industry

Company Name Region
Nucelis Inc. United States
Schepens Eye Research Institute Inc. United States
Innovate Biopharmaceuticals, Inc. United States
Genteric, Inc. United States
MIGENIX Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fabrus, LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at